Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions
{
"resourceType" : "Group",
"id" : "179785",
"meta" : {
"versionId" : "4",
"lastUpdated" : "2023-12-04T20:30:06.799Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-definition"
]
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: Group</b><a name=\"179785\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource Group "179785" Version "4" Updated "2023-12-04 20:30:06+0000" </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-comparator-definition.html\">ComparatorDefinition</a></p></div><p><b>Artifact related artifact</b>: </p><p><b>Artifact Title</b>: ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis</p><p><b>Artifact URL</b>: <a href=\"https://fevir.net/resources/Group/179785\">https://fevir.net/resources/Group/179785</a></p><p><b>Artifact Publisher</b>: Computable Publishing LLC</p><p><b>Artifact Copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>Artifact Contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>CombinationMethod</b>: any-of</p><blockquote><p><b>modifierExtension[http://hl7.org/fhir/StructureDefinition/artifact-status]</b></p></blockquote><p><b>identifier</b>: FEvIR Object Identifier:\u00a0179785</p><p><b>type</b>: animal</p><p><b>membership</b>: definitional</p><p><b>name</b>: ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis</p><p><b>description</b>: Description: usual-care pharmacologic thromboprophylaxis\nNote: Thromboprophylaxis was provided at a dose and duration determined by the treating clinician according to local practice.\nNote: Usual-care pharmacological thromboprophylaxis included both intermediate-intensity (in 27%) and prophylactic-intensity dosing (in 72%). Subgroup analyses may be informative to determine if there is a difference related to the intensity used in the control arm of the trial.</p><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: ATTACC comparator arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>value</b>: Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be more than half of the approved therapeutic dose for the treatment of venous thromboembolism. <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: ACTIV-4a comparator arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>value</b>: Any one of enoxaparin, dalteparin, tinzaparin, fondaparinux, or heparin according to local preference. Dose of agent specified to be consistent with guidelines for low dose thromboprophylaxis. <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: REMAP-CAP comparator arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>value</b>: Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be sufficient to result in therapeutic anticoagulation. <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>exclude</b>: false</p></blockquote></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact",
"valueRelatedArtifact" : {
"type" : "cite-as",
"citation" : "ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179785. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179785. Computable resource at: https://fevir.net/resources/Group/179785."
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-title",
"valueString" : "ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-url",
"valueUri" : "https://fevir.net/resources/Group/179785"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-publisher",
"valueString" : "Computable Publishing LLC"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-copyright",
"valueMarkdown" : "https://creativecommons.org/licenses/by-nc-sa/4.0/"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-contact",
"valueContactDetail" : {
"telecom" : [
{
"system" : "email",
"value" : "support@computablepublishing.com"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail" : {
"name" : "Brian S. Alper"
}
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method",
"valueCode" : "any-of"
}
],
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-status",
"valueCode" : "active"
}
],
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net",
"value" : "179785",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"type" : "animal",
"membership" : "definitional",
"name" : "ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis",
"description" : "Description: usual-care pharmacologic thromboprophylaxis\nNote: Thromboprophylaxis was provided at a dose and duration determined by the treating clinician according to local practice.\nNote: Usual-care pharmacological thromboprophylaxis included both intermediate-intensity (in 27%) and prophylactic-intensity dosing (in 72%). Subgroup analyses may be informative to determine if there is a difference related to the intensity used in the control arm of the trial.",
"characteristic" : [
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description",
"valueMarkdown" : "ATTACC comparator arm"
},
{
"extension" : [
{
"url" : "contextCode",
"valueCodeableConcept" : {
"text" : "Start of trial"
}
},
{
"url" : "offset",
"valueRange" : {
"low" : {
"value" : 0
},
"high" : {
"value" : 14,
"unit" : "days",
"system" : "http://unitsofmeasure.org",
"code" : "d"
}
}
},
{
"url" : "text",
"valueString" : "Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."
}
],
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing"
}
],
"code" : {
"text" : "Defined by CodeableConcept"
},
"valueCodeableConcept" : {
"text" : "Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be more than half of the approved therapeutic dose for the treatment of venous thromboembolism."
},
"exclude" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description",
"valueMarkdown" : "ACTIV-4a comparator arm"
},
{
"extension" : [
{
"url" : "contextCode",
"valueCodeableConcept" : {
"text" : "Start of trial"
}
},
{
"url" : "offset",
"valueRange" : {
"low" : {
"value" : 0
},
"high" : {
"value" : 14,
"unit" : "days",
"system" : "http://unitsofmeasure.org",
"code" : "d"
}
}
},
{
"url" : "text",
"valueString" : "Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."
}
],
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing"
}
],
"code" : {
"text" : "Defined by CodeableConcept"
},
"valueCodeableConcept" : {
"text" : "Any one of enoxaparin, dalteparin, tinzaparin, fondaparinux, or heparin according to local preference. Dose of agent specified to be consistent with guidelines for low dose thromboprophylaxis."
},
"exclude" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description",
"valueMarkdown" : "REMAP-CAP comparator arm"
},
{
"extension" : [
{
"url" : "contextCode",
"valueCodeableConcept" : {
"text" : "Start of trial"
}
},
{
"url" : "offset",
"valueRange" : {
"low" : {
"value" : 0
},
"high" : {
"value" : 14,
"unit" : "days",
"system" : "http://unitsofmeasure.org",
"code" : "d"
}
}
},
{
"url" : "text",
"valueString" : "Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."
}
],
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing"
}
],
"code" : {
"text" : "Defined by CodeableConcept"
},
"valueCodeableConcept" : {
"text" : "Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be sufficient to result in therapeutic anticoagulation."
},
"exclude" : false
}
]
}
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2023-12-17
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change